NCT06976320

Brief Summary

Postoperative pain after laparoscopic cholecystectomy can be considerable. Regional techniques such as erector spinae plane (ESP) block or transversus abdominis plane (TAP) block may be suitable for patients at increased risk of postoperative pain. The deep rectus sheath block is a novel block which is a modified version of the conventional rectus sheath block. It was reported in a few case reports that, it may be used for postoperative analgesia in patients undergoing laparoscopic cholecystectomy. The aim of this study is to investigate the postoperative analgesic efficacy of deep rectus sheath block in patients undergoing laparoscopic cholecystectomy.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 9, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 16, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

September 9, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

September 22, 2025

Status Verified

September 1, 2025

Enrollment Period

3 months

First QC Date

May 9, 2025

Last Update Submit

September 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Morphine consumption

    The amount of morphine required by the patient and given by the device will be recorded for the first 24 hours.

    Postoperative 24 hours

Secondary Outcomes (3)

  • Postoperative numerical rating scale scores

    Postoperative 24 hours

  • Rescue analgesic drug requirement

    Postoperative 24 hours

  • Incidence of postoperative nausea and vomiting

    Postoperative 24 hours

Study Arms (2)

Control group

ACTIVE COMPARATOR

The patients in Control Group will be received patient controlled analgesia with morphine for postoperative analgesia

Other: Intravenous morphine patient control analgesia

Deep rectus sheath block group

ACTIVE COMPARATOR

The patients in deep rectus sheath block group will be received deep rectus sheath block and patient controlled analgesia with morphine for postoperative analgesia

Other: Intravenous patient control analgesiaOther: Deep rectus sheath block

Interventions

24-hour morphine consumption will be recorded

Control group

24-hour morphine consumption will be recorded

Deep rectus sheath block group

Deep rectus sheath block will be administered at the end of the surgery.

Deep rectus sheath block group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 80 years
  • Patients with American Society of Anesthesiology (ASA) physical status I-II
  • Patients scheduled for a laparoscopic cholecystectomy

You may not qualify if:

  • Allergy to local anesthetics
  • Coagulopathy
  • Skin infection at the deep rectus sheath block area
  • Advanced hepatic or renal failure
  • Chronic pain syndromes
  • Alcohol or drug abuse
  • Severe pulmonary and/or cardiovascular disease
  • Psychiatric disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istinye University Hospital

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Taylan Sahin, M.D.

    Istinye University

    PRINCIPAL INVESTIGATOR
  • Ali Sait Kavakli, M.D.

    Istinye University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Taylan Sahin, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2025

First Posted

May 16, 2025

Study Start

September 9, 2025

Primary Completion

December 1, 2025

Study Completion

January 1, 2026

Last Updated

September 22, 2025

Record last verified: 2025-09

Locations